INTO is a unique alliance in the field of inhalation development services established by DFE Pharma, Harro Höfliger and Sterling in February 2022.
Find out more about our story
Our aim is to support customers in making their respiratory product (Innovative, generics, high dose or biologic formulations) development fast, economic and easy to manage by offering our overarching view, combined expertise and coordinated approach.
Find out more about our offerings and solutions here
Understanding the appropriate Active Ingredient for your product, by looking at the physical and chemical properties.
Understanding the critical quality attributes,by identifying the key variables and employing risk-based strategies.
Creating, optimizing, and validating analytical methods to assess product quality and performance throughout its development.
Personalized and individual inhalation consultation through all development steps.
CPHI worldwide
Milan, Italy
8.-10. October 2024
Drug Delivery to the Lungs
Edinburgh, Scotland
11.-13. December 2024